235 related articles for article (PubMed ID: 22072494)
21. Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.
Saylor PJ; Smith MR; O'Malley AJ; Keating NL
Eur Urol; 2014 Mar; 65(3):642-9. PubMed ID: 23428068
[TBL] [Abstract][Full Text] [Related]
22. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
Jespersen CG; Nørgaard M; Borre M
Eur Urol; 2014 Apr; 65(4):704-9. PubMed ID: 23433805
[TBL] [Abstract][Full Text] [Related]
23. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
24. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
[TBL] [Abstract][Full Text] [Related]
25. Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania.
Drevinskaite M; Patasius A; Kincius M; Urbonas V; Smailyte G
BMJ Open; 2021 Jul; 11(7):e045797. PubMed ID: 34321292
[TBL] [Abstract][Full Text] [Related]
26. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.
Azoulay L; Yin H; Benayoun S; Renoux C; Boivin JF; Suissa S
Eur Urol; 2011 Dec; 60(6):1244-50. PubMed ID: 21908097
[TBL] [Abstract][Full Text] [Related]
27. Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
Liu R; Zhou J; Xia S; Li T
Urol Int; 2020; 104(3-4):214-221. PubMed ID: 31747673
[TBL] [Abstract][Full Text] [Related]
28. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
29. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study.
Klil-Drori AJ; Santella C; Tascilar K; Yin H; Aprikian A; Azoulay L
Drug Saf; 2019 Aug; 42(8):1005-1011. PubMed ID: 31240687
[TBL] [Abstract][Full Text] [Related]
30. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
[TBL] [Abstract][Full Text] [Related]
31. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
32. Risk of fracture after androgen deprivation for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
N Engl J Med; 2005 Jan; 352(2):154-64. PubMed ID: 15647578
[TBL] [Abstract][Full Text] [Related]
33. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
34. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.
Yang DD; Krasnova A; Nead KT; Choueiri TK; Hu JC; Hoffman KE; Yu JB; Spratt DE; Feng FY; Trinh QD; Nguyen PL
Ann Oncol; 2018 Feb; 29(2):386-391. PubMed ID: 29267861
[TBL] [Abstract][Full Text] [Related]
35. Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.
Suarez-Almazor ME; Peddi P; Luo R; Nguyen HT; Elting LS
Support Care Cancer; 2014 Feb; 22(2):537-44. PubMed ID: 24146343
[TBL] [Abstract][Full Text] [Related]
36. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
37. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
38. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
Young JWS; Sutradhar R; Rangrej J; Marras C; Fleshner N; Alibhai SMH
World J Urol; 2017 Sep; 35(9):1417-1423. PubMed ID: 28204918
[TBL] [Abstract][Full Text] [Related]
39. Cancer Therapy-Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.
Chen DY; Lee CH; Tsai ML; Hsieh MJ; Chuang CK; Pang ST; Chen SW; Tseng CN; Chang SH; Chu PH; Hsieh IC; Wu VC; Huang WK
J Am Heart Assoc; 2023 Oct; 12(19):e030447. PubMed ID: 37750600
[TBL] [Abstract][Full Text] [Related]
40. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.
Meng F; Zhu S; Zhao J; Vados L; Wang L; Zhao Y; Zhao D; Niu Y
BMC Cancer; 2016 Mar; 16():180. PubMed ID: 26940836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
